{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-212159","form_type":"8-K","ticker":"STE","cik":"0001757898","company_name":"STERIS plc","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.861375+00:00","generated_at":"2026-05-14T21:55:44.421388+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"STERIS appoints Pierre Boulud to board; Richard Breeden to retire at 2026 AGM","bullets":["Richard C. Breeden notified he will not stand for reelection at 2026 AGM; retirement not due to any disagreement.","Board increased from 9 to 10 members; Pierre Boulud appointed director effective May 5, 2026.","Boulud is CEO of bioMérieux (in vitro diagnostics); previously COO at bioMérieux and exec at Ipsen.","Boulud receives prorated fee of $76,989 in restricted stock units for remainder of board term."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-212159","json":"https://secwatch.observer/filing/0001193125-26-212159.json","markdown":"https://secwatch.observer/filing/0001193125-26-212159.md","text":"https://secwatch.observer/filing/0001193125-26-212159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/0001193125-26-212159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/d27562d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:55:44.421388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"443083eb4f","claim":"Richard C. Breeden departed as Director at STERIS plc.","evidence_excerpt":"On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/0001193125-26-212159-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for reelection"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b204abb94c","claim":"Pierre Boulud was appointed as Director at STERIS plc.","evidence_excerpt":"On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/0001193125-26-212159-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}